INOVIO Pharmaceuticals
NEWS ALERT

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Press Releases

INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024

Posted on February 21, 2024

INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Posted on February 7, 2024

INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split

Posted on January 31, 2024

INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader

Posted on January 22, 2024

INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)

Posted on January 4, 2024

INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program

Posted on January 3, 2024

INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program

Posted on October 10, 2023

INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Posted on September 7, 2023

INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Posted on August 29, 2023

INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update

Posted on August 9, 2023

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.